Biogen Inc. (NASDAQ: BIIB) announced results from its Phase 2 CELIA study of diranersen, an investigational antisense oligonucleotide therapy targeting ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Mizuho Reiterates Outperform Rating on Biogen (BIIB)May 14, 2026 8:17 AM Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'May 14, 2026 7:44 AM Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'May 14, 2026 7:29 AM